醋酸亮丙瑞林对子宫内膜异位症患者VEGF和CEA及CA125水平的影响

Effect of Lepirelin Acetate on VEGF, CEA and CA125 Levels in Patients with Endometriosis and Safety Analysis

目的:探究醋酸亮丙瑞林对子宫内膜异位症患者血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)及糖类抗原125(CA125)水平的影响。方法:140例子宫内膜异位症患者随机均分为对照组(炔雌醇环丙孕酮片治疗)及观察组(注射用醋酸亮丙瑞林微球治疗),连续治疗4个月;治疗前及治疗4个月时,采用酶联免疫吸附法(ELISA)检测2组患者血清VEGF、CEA、CA125、雌二醇(E 2)、黄体生成素(LH)及卵泡刺激素(FSH)水平,采用视觉模拟疼痛(VAS)评分评估患者腹部疼痛、采用月经失血图(PBAC)评分评估患者患者月经量、观察并记录患者治疗期间不良反应发生情况。结果:治疗4个月时,2组患者血清VEGF、CA125、E 2、LH及FSH均较治疗前降低(P<0.01),观察组低于对照组(P<0.05);血清CEA水平比较,仅对照组治疗4个月时高于治疗前(P<0.05);治疗4个月时2组患者VAS评分、PBAC评分均较治疗前降低,且观察组低于对照组(P<0.05或P<0.01);2组患者治疗期间不良反应检出率差异无统计学意义(χ2=0.201,P=0.654)。结论:醋酸亮丙瑞林可有效缓解子宫内膜异位症患者腹部疼痛及减少月经量,其机制可能有降低血清VEGF和CA125水平,抑制雌激素分泌有关。

Objective:To investigate the effect and safety of lepirelin acetate on serum levels of vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in patients with endometriosis.Methods:140 patients with endometriosis were randomly divided into the control group(treatment with ethinylestradiol and progesterone tablets)and the observation group(treatment with lebulin acetate microspheres for injection)for 4 months.By using enzyme-linked immunosorbent(ELISA)detection of two groups of patients before and after the April treatment VEGF,CEA,CA125,estradiol(E2),luteinizing hormone(LH)and follicle-stimulating hormone(FSH)levels,using visual analog pain score(VAS)assessment of patients with abdominal pain,menstrual blood loss figure(PBAC)score evaluation menstrual quantity,observe and record the patient treatment in patients with adverse reactions occurred during the study.Results:After treatment,serum VEGF and CEA levels in both groups were significantly lower than those before treatment.Serum VEGF and CA125 levels in the observation group were significantly lower than those in the control group(P<0.01),while serum CEA levels in the control group were higher than those before treatment(P<0.05).After treatment,serum E2,LH and FSH in the two groups were lower than those before treatment,and were significantly lower in the observation group than in the control group(P<0.05 or P<0.01).VAS score and PBAC score in both groups after treatment were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05 or P<0.01).There was no significant difference in the detection rate of adverse reactions between the two groups(χ2=0.201,P=0.654).Conclusion:Lepirelin acetate can effectively relieve abdominal pain and reduce menstrual flow in patients with endometriosis,and the mechanism may be related to lowering serum VEGF and CA125 levels and inhibiting estrogen secretion.